About Telavant
Telavant is a Healthcare company based in New York (United States) founded in 2022, and was acquired by Roche in October 2023. Therapeutics for inflammatory and fibrotic diseases are developed. Its chief executive, as recorded, is Frank Torti. Telavant offers products and services including Susvimo and Diagnostic Solutions. Its focus areas include Life Sciences, Immunology, Drugs and Diversified. Its legal entity is F. Hoffmann-La Roche Ltd. Its competitors include Biogen, ADMA Biologics and Kymeratx; 3 of its 3 listed competitors have raised funding.
Company details
Telavant was founded in 2022 and is headquartered in New York, United States. Focus is placed on the biotechnology sector, where therapeutics targeting inflammatory and fibrotic conditions are developed. Operations center on advancing biologic candidates, including the lead asset RVT-3101, a human monoclonal antibody directed at TL1A. This therapy is formulated for subcutaneous administration to address ulcerative colitis and Crohns disease in patients.
- Headquarters New York, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website telavanttx.com
- Social LinkedIn
- Acquired by Roche (Oct 2023)
- Legal Name F. Hoffmann-La Roche Ltd
Products & Services of Telavant
Telavant offers a comprehensive portfolio of products and services, including Susvimo and Diagnostic Solutions.
Treatment for diabetic macular edema via continuous delivery.
Products for accurate disease diagnosis and patient stratification.
Investors in Telavant
Telavant has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Roche.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceuticals and diagnostics kits are developed for various diseases. | 1896 | roche.com | Basel, Switzerland |
Investor details for Telavant
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Telavant
1 people are tracked at Telavant (1 in leadership).
| Name | Role | Group |
|---|---|---|
Frank Torti | CEO | Leadership |
Complete people profiles for Telavant
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Telavant
2 dated milestones of Telavant across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Telavant is founded.
- Exit Acquired by Roche.
Competitors of Telavant
Telavant has 3 listed competitors in our database, 3 of them funded. They include Biogen, ADMA Biologics and Kymeratx.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| admabiologics.com | 2005 | Ramsey, United States | $17.55M | 498 | Plasma-based biologics are developed for immune deficiency and infectious diseases. | |
| kymeratx.com | 2016 | Cambridge, United States | $197M | 150 | Small molecule protein degraders are developed for various disorders. |
Detailed competitors of Telavant
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Telavant (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Telavant
Telavant was founded in 2022.
Telavant is headquartered in New York, United States. It is registered at New York, New York, United States.
Frank Torti is the CEO of Telavant, as recorded in our data.
Telavant was founded in 2022 and is headquartered in New York, United States. Focus is placed on the biotechnology sector, where therapeutics targeting inflammatory and fibrotic conditions are developed. Operations center on advancing biologic candidates, including the lead asset RVT-3101, a human monoclonal antibody directed at TL1A. This therapy is formulated for subcutaneous administration to address ulcerative colitis and Crohns disease in patients.
Telavant's top competitors include ADMA Biologics, Kymeratx and Biogen.
Telavant offers Susvimo and Diagnostic Solutions.
Telavant has 1 investor. Key investors include Roche.
Telavant operates through F. Hoffmann-La Roche Ltd.
Yes. Telavant was acquired by Roche in October 2023.